Event Title

Global Perspectives of Data Exclusivity

Panel

Panel 2: IP, Trade and Access

Moderator

Henry Liao, Partner, Schinders Law

Description

The presentation will focus on how pharmaceutical companies have expertly navigated the confluence of patents with regulatory data protection to leverage the market in order to effectively create increased protection and financial rewards for materials that could otherwise be susceptible to generic competition. The focus of the presentation will be on the international trade obligations relating to providing data exclusivity, and the solution to alleviate the adverse impact of data exclusivity obligations on access to medication with a specific focus on developing countries while keeping the US regime as the vantage point to examine the issues.

Speaker Bio

Ragavan is a Professor of Law at the Texas A&M School of Law. Ragavan’s scholarship focuses on the interplay between international trade law and intellectual property issues with a developmental perspective. Her work emphasizes issues that affect developing nations from embracing the trade regime. Her publications have expounded diverse topics like traditional knowledge, pharmaceutical patenting and agricultural subsidies.

Location

Pacific McGeorge School of Law, Lecture Hall, 3200 Fifth Ave., Sacramento, CA

This document is currently not available here.

Share

COinS
 
Apr 5th, 9:25 AM Apr 5th, 10:25 AM

Global Perspectives of Data Exclusivity

Pacific McGeorge School of Law, Lecture Hall, 3200 Fifth Ave., Sacramento, CA

The presentation will focus on how pharmaceutical companies have expertly navigated the confluence of patents with regulatory data protection to leverage the market in order to effectively create increased protection and financial rewards for materials that could otherwise be susceptible to generic competition. The focus of the presentation will be on the international trade obligations relating to providing data exclusivity, and the solution to alleviate the adverse impact of data exclusivity obligations on access to medication with a specific focus on developing countries while keeping the US regime as the vantage point to examine the issues.